Be Biopharma is developing engineered B cell therapies to treat serious diseases, focusing on conditions like hemophilia B. Their approach utilizes protein-based treatments to enhance patient outcomes and improve quality of life for those affected.
Funding
$264M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for diseases like hemophilia B often fall short of providing a complete and lasting solution, requiring frequent interventions and failing to fully address the underlying genetic or biological deficits. This can lead to a reduced quality of life for patients and a continued burden on healthcare systems.
Solution
Be Biopharma is developing engineered B cell medicines (BCMs) designed to offer transformative treatments for serious diseases. Their approach focuses on harnessing the therapeutic potential of B cells to address conditions such as hemophilia B and hypophosphatasia. By engineering B cells, Be Biopharma aims to create therapies that can provide long-term benefits and potentially curative outcomes for patients. These B cell medicines are designed to correct the underlying causes of disease, offering a more sustainable and effective treatment option compared to traditional approaches. The company is advancing its science with a focus on improving patient outcomes and transforming the care landscape for individuals living with serious diseases.
Target Audience
The primary target audience includes patients with serious diseases such as hemophilia B and hypophosphatasia, as well as healthcare providers and specialists involved in their care.
Features
- Utilizes engineered B cells to address the underlying causes of disease.
- Focuses on developing potentially curative therapies for conditions like hemophilia B and hypophosphatasia.
- Aims to provide long-term benefits and reduce the need for frequent interventions.
- Developing best-in-class B cell medicines.